Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | TERT | O14746 | 2/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744447 | 0.90 | KDM1A (0.43) | KDM1A | |
| SCHEMBL23464921 | 0.82 | KDM1A (0.46) | KDM1ACARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12991750 | 0.79 | KCNA3 (0.39) | TERTKCNA3SPHK1MAPK1ATM | |
| SCHEMBL12744445 | 0.79 | CARM1 (0.46) | KDM1AMAPK1CARM1PRMT6PRMT8 | |
| SCHEMBL5481364 | 0.77 | KCNA3 (0.40) | TERTKCNA3SPHK1MAPK1ATM | |
| SCHEMBL12744429 | 0.77 | CARM1 (0.45) | KDM1AMAPK1CARM1PRMT6PRMT8 | |
| SCHEMBL13451388 | 0.77 | KDM1A (0.43) | KDM1AHTR1AHTR1DHTR1BSMN1; SMN2 | |
| SCHEMBL12668629 | 0.76 | KCNA3 (0.39) | TERTKCNA3SPHK1MAPK1ATM | |
| SCHEMBL13588739 | 0.75 | KCNA3 (0.39) | TERTKCNA3SPHK1MAPK1ATM | |
| SCHEMBL12744432 | 0.74 | KDM1A (0.41) | KDM1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910611-B2 | Therapeutic agent for restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100029625-A1 | Therapeutic Agent for Restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029625-A1 | Therapeutic Agent for Restenosis | NR1H2, NR1H3, LDLR | KDM1A 3976/4885TERT 3742/4885KCNA3 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.